Key result
Point-of-care cardiac troponin-T testing resulted in similar 3-month adverse outcomes compared with laboratory testing.
Why the study?
Does point-of-care cardiac troponin-T testing reduce adverse clinical outcomes compared to laboratory-based testing in adults suspected of acute coronary syndrome?
RCT (n=452)
randomised
Does point-of-care cardiac troponin-T testing reduce adverse clinical outcomes compared to laboratory-based testing in adults suspected of acute coronary syndrome?
Point-of-care cardiac troponin-T testing resulted in similar 3-month adverse clinical outcomes compared to laboratory-based testing in patients with suspected ACS, though the small sample size limits definitive conclusions.
Answers are grounded in this paper and cite their sources.
Supports point-of-care troponin-T testing as a safe alternative in suspected ACS; leaves open definitive noninferiority due to small sample and wide CI.
OBJECTIVE: The aim of this randomised trial was to determine clinical outcomes in patients suspected of an acute coronary syndrome (ACS) who had cardiac troponin-T measured by point-of-care (POC) compared with laboratory-based cardiac troponin-T testing. A secondary aim was to describe the correlation between the two troponin assays. METHODS: Adults suspected of ACS were allocated to have troponin processed by POC or laboratory analyser. The primary outcome was a composite of acute myocardial infarction, coronary revascularisation, cardiac arrest and mortality at 3 months. Paired troponins taken on participants allocated to POC were used to determine correlation between troponin values obtained from laboratory and POC analysers. RESULTS: There were 452 participants. 30 (13.1%) of 229 participants allocated to POC had at least one primary outcome event compared with 29 (13.0%) of 223 allocated to laboratory testing, a difference of 0.1% (95% CI -6.2% to 6.4%, p=0.98). Of 215 available paired troponins results, both analysers gave congruent results in 196 (91%) cases. The POC troponin was negative when the laboratory sample was positive in 16 (7%) cases. The POC troponin was positive when the laboratory sample was negative in 3 (1%) samples. Passing-Bablok regression analysis demonstrated both a constant and proportional difference between the two analytic methods. CONCLUSIONS: Among patients suspected of an ACS, we found no evidence for a difference in adverse outcome when POC troponin was used in comparison with laboratory troponin. Due to the small sample size, an absolute difference of up to 6% in adverse outcome is possible. TRIAL REGISTRATION NUMBER: ANZCTR#12612000319875.
No takes yet. Share an insight, caveat, or question.
Asha et al. (2014) conducted an RCT in suspected acute coronary syndrome (n=452). Point-of-care (POC) cardiac troponin-T testing vs. Laboratory-based cardiac troponin-T testing was evaluated on composite of acute myocardial infarction, coronary revascularisation, cardiac arrest and mortality at 3 months (difference 0.1%, 95% CI -6.2% to 6.4%, p=0.98). Point-of-care cardiac troponin-T testing resulted in similar 3-month adverse outcomes compared with laboratory testing.
Synapse has enriched 10 related papers. Consider them for comparative context: